참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 1-Acetylpiperazine | HCID 83795 | — |
| 반응물 | 4-Bromo-2-nitroanisole | HCID 118533 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | 1-[4-(4-Methoxy-3-nitro-phenyl)-piperazin-1-yl]ethanone | HCID 58235711 | 85.85% |
반응 단계
diacetoxypalladium (2.322 g, 10.34 mmol) was added to a stirred suspension of 4-bromo-1-methoxy-2-nitrobenzene (30 g, 129.29 mmol), 1-(piperazin-1-yl)ethanone (16.57 g, 129.29 mmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (8.98 g, 15.52 mmol) and cesium carbonate (84 g, 258.59 mmol) dissolved in dioxane (300 mL) , degased and under argon. The resulting suspension was stirred at 120 °C for 2 hours.At 25°C, the mixture was filtered and adsorbed on silica gel .The crude product was purified by flash chromatography on silica gel eluting with 1 to 5% methanol in ethyle acetate. The solvent was evaporated to dryness to afford 1-(4-(4-methoxy-3-nitrophenyl)piperazin-1-yl)ethanone (31.0 g, 86 %) as a orange solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-77e8bb12d76a4a1d94f2c62d1d96fda1 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|